Comedian Nathan Fielder shares what he learned being a 737 pilot on new season of HBO's ‘The Rehearsal'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Evercore ISI Maintains a Buy on Enovis Corporation (ENOV) With a $46 PT
Enovis Corporation (NYSE:ENOV) is one of the best undervalued medical device stocks to buy now. In a report released on July 8, Vijay Kumar from Evercore ISI maintained a Buy rating on Enovis Corporation (NYSE:ENOV) and set a price target of $46.00. A patient recieving cold therapy treatment using the company's products. The company reported continued commercial momentum in fiscal Q1 2025 results, with net sales for the quarter reaching $559 million and reported an 8% growth on a reported basis and 9% rise on a comparable basis from the same quarter last year. Reconstructive sales for the quarter rose 11% year-over-year on a reported basis. Enovis Corporation's (NYSE:ENOV) fiscal Q1 2025 results show a rebound in growth in Recon, net sales for which grew 11% on a reported and comparable basis. The company also showed accelerating momentum in new product introductions and continued execution in P&R, reflecting a 5% growth on a reported basis and 7% on a comparable growth basis. Enovis Corporation (NYSE:ENOV) is a medical technology growth company that develops clinically differentiated solutions to transform workflows and generate better patient outcomes. The company operates through the Prevention & Recovery and Reconstructive segments. While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
4 minutes ago
- Yahoo
Truist Financial Remains Bullish on AdaptHealth (AHCO)
AdaptHealth Corp. (NASDAQ:AHCO) is one of the best undervalued medical device stocks to buy now. In a report released on July 1, David S Macdonald from Truist Financial maintained a Buy rating on AdaptHealth Corp. (NASDAQ:AHCO) without a price target. A healthcare professional wearing a face mask and surgical gloves operating a medical device in a clinical setting. AdaptHealth Corp. (NASDAQ:AHCO) reported $95.5 million in cash flow from operations in fiscal Q1 2025, an increase from $49.0 million. Free cash flow for the quarter reached negative $0.1 million, compared to negative $38.9 million previously. Net revenue for the quarter, however, underwent a 1.8% decline to $777.9 million. AdaptHealth Corp. (NASDAQ:AHCO) provides home healthcare equipment, supplies, and related services. The company's focus is on sleep therapy equipment for obstructive sleep apnea, oxygen, and related chronic therapy services, HME medical devices and supplies for wound care, diabetes, urological, and more. While we acknowledge the potential of AHCO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)
Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best oversold NASDAQ stocks to buy now. On June 20, Mizuho analyst Salim Syed commented on Vaxcyte, Inc. (NASDAQ:PCVX), on which the firm maintained an Outperform rating. Syed's comment followed reports that Health and Human Services Secretary Kennedy was considering a review of licensed vaccines containing aluminum adjuvants. A research scientist in a laboratory holding a vial of a biotechnology drug. The analyst told investors in a research note that this development is significant for Vaxcyte, Inc. (NASDAQ:PCVX), as its pneumococcal vaccine candidates contain aluminum adjuvant at levels similar to those found in Merck's Vaxneuvance and Pfizer's Prevnar 20. The firm stated that aluminum adjuvants are present in several vaccines recommended by the Centers for Disease Control and Prevention for infants and children and have been used widely since the 1930s. It added that the FDA's work shows that aluminum exposure from vaccines is safe, and sees the 'preponderance of evidence' as supporting the use of aluminum adjuvants in vaccines. Mizuho thus stated that if a review of licensed vaccines containing aluminum adjuvant is carried out, it 'will prove this out.' Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company that develops high-fidelity vaccines. It develops broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. The company re-engineers the creation of highly complex vaccines through advanced chemistry and modern synthetic techniques. While we acknowledge the potential of PCVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
